Back to search

Article

Real-world safety and relative dose intensity of upfront enzalutamide in metastatic castration-sensitive prostate cancer

2026-06-05

Abstract excerpt

<title>Abstract</title> <p>Background Upfront enzalutamide improves outcomes in metastatic castration-sensitive prostate cancer; however, real-world data on adverse events, dose modification, and treatment intensity remain limited. This study evaluated the adverse event profile and clinical impact of treatment intensity during enzalutamide therapy. Methods We retrospectively analyzed 112 patients with metastati...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3614e60f-7f88-5122-85ac-e1357d534d52
DOI
10.21203/rs.3.rs-9835399/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Real-world safety and relative dose intensity of upfront enzalutamide in metastatic castration-sensitive prostate cancerDOI 10.21203/rs.3.rs-9835399/v1
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysisSemantic proximity
Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate CancerSemantic proximity
Inhibition of Galectin-1 and androgen receptor axis enhances enzalutamide treatment in enzalutamide resistant prostate cancerSemantic proximity
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancerSemantic proximity
Effects of enzalutamide, apalutamide, and darolutamide in metastatic hormone-sensitive prostate cancer with or without docetaxel: a systematic review and network meta-analysisSemantic proximity
Bone Scan Index (BSI) scoring by using bone scintigraphy and circulating tumor cells (CTCs): predictive factors for enzalutamide effectiveness in patients with castration-resistant prostate cancer and bone metastasesSemantic proximity
A Glutamine antagonist-modulated tumor microenvironment unleashes enzalutamide’s immunotherapeutic effectsSemantic proximity
Optimal Treatment Sequence for Metastatic Castration-resistant Prostate CancerSemantic proximity
Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancerSemantic proximity
A Drug-Specific, Half-Life-Adjusted Framework for Classifying CNS-Active Systemic Therapy Exposure During and After RadiotherapySemantic proximity
Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancerSemantic proximity
Design, synthesis and evaluation of novel enzalutamide analogues as potential anticancer agentsSemantic proximity
Select a neighboring publication to make it the new centre.